ASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation

Stock News

06/08

ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana. The presentations highlighted the company's differentiated pipeline in obesity treatment, featuring a small molecule candidate, a peptide drug, and an oral peptide delivery enhancement technology.

The data showcased at the event garnered significant attention from leading experts in attendance, further underscoring ASCLETIS-B's innovative capabilities in the field of metabolic disease therapies.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1102346844"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102346844\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102346844?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 08:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102346844","market":"us","top_or_hot":-1,"title":"ASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation","media":"Stock News","content":"<p>ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana. The presentations highlighted the company's differentiated pipeline in obesity treatment, featuring a small molecule candidate, a peptide drug, and an oral peptide delivery enhancement technology.<br><br>The data showcased at the event garnered significant attention from leading experts in attendance, further underscoring ASCLETIS-B's innovative capabilities in the field of metabolic disease therapies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B Presents Compelling Clinical and Preclinical Data for Obesity Portfolio at ADA 2026, Reinforcing Pipeline Differentiation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-06-08 08:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana. The presentations highlighted the company's differentiated pipeline in obesity treatment, featuring a small molecule candidate, a peptide drug, and an oral peptide delivery enhancement technology.<br><br>The data showcased at the event garnered significant attention from leading experts in attendance, further underscoring ASCLETIS-B's innovative capabilities in the field of metabolic disease therapies.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"歐康維視生物-B","start_time":0,"source_url":"","article_id":"1102346844","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102346844","pubTimestamp":1780877777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B","BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","01672":"歌礼制药-B"},"translate_title":"歌礼-B在ADA 2026上展示了令人信服的肥胖产品组合临床和临床前数据，加强了产品线的差异化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1,"01477":1},"content_text":"ASCLETIS-B (01672) has announced that three pivotal studies were presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, held from June 5th to 8th in New Orleans, Louisiana. The presentations highlighted the company's differentiated pipeline in obesity treatment, featuring a small molecule candidate, a peptide drug, and an oral peptide delivery enhancement technology.The data showcased at the event garnered significant attention from leading experts in attendance, further underscoring ASCLETIS-B's innovative capabilities in the field of metabolic disease therapies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}